NCT05816083 Development and Evaluation of a Virtual Reality Tool for At-Risk Trauma-Exposed Young People
| NCT ID | NCT05816083 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical University of South Carolina |
| Condition | Substance Use Disorders |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-02-06 |
| Primary Completion | 2026-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2025-02-06 with a primary completion date of 2026-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a multi-phased study, funded through a National Institute on Drug Abuse (NIDA) K24 grant that aims to ultimately refine a virtual reality tool through qualitative and quantitative research targeting HIV and substance abuse risk behavior among at-risk young people who have experienced psychosocial trauma. Participants eligible for this study include young men who have sex with men (YMSM)/individuals who are romantically/physically attracted to men and adolescents with substance use disorder (SUD) between the ages of 15 - 30 and have experienced at least one traumatic event in their lifetime. Frontline healthcare workers who work within these populations are eligible for the study as well.
Eligibility Criteria
Inclusion Criteria for YMSM are as follows: * Someone who identifies as a YMSM or identifies as someone with romantic or physical attraction to individuals who identify as men * Is aged 15-30 years * Have experienced at least one ITE in lifetime (i.e., sexual assault, physical assault, witnessed domestic or community violence) * Report being consensually sexually active or planning to become sexually active with a partner in the next 12 months * Live in the Charleston, SC/Tri-county area Inclusion Criteria for adolescents with SUD are as follows: * Someone who reports using substances in the past year (for participants ages 15-17) or the past 6 months (for participants ages 18-30) * Is aged 15-30 years * Have experienced at least one ITE in lifetime (i.e., sexual assault, physical assault, witnessed domestic or community violence) * Report being consensually sexually active or planning to become sexually active with a partner in the next 12 months * Live in the Charleston, SC/Tri-county area Inclusion Criteria for front line healthcare workers are as follows: * works directly with adolescents who have experienced ITE and/or * works directly with adolescents or young adults with SUD and/or * works directly with YMSM and/or * works directly with and/or adolescent or young adults who are HIV-positive Exclusion Criteria for all participants are as follows: * exhibits psychotic symptoms; * exhibits significant cognitive disability; * reports a history of Pervasive Developmental Disorder; * has active suicidal or homicidal ideations * self-reports high levels of motion sickness
Contact & Investigator
Danielson
PRINCIPAL INVESTIGATOR
Medical University of South Carolina
Frequently Asked Questions
Who can join the NCT05816083 clinical trial?
This trial is open to participants of all sexes, aged 15 Years or older, up to 30 Years, studying Substance Use Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05816083 currently recruiting?
Yes, NCT05816083 is actively recruiting participants. Contact the research team at kirbych@musc.edu for enrollment information.
Where is the NCT05816083 trial being conducted?
This trial is being conducted at Charleston, United States.
Who is sponsoring the NCT05816083 clinical trial?
NCT05816083 is sponsored by Medical University of South Carolina. The principal investigator is Danielson at Medical University of South Carolina. The trial plans to enroll 50 participants.